Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Ottawa

$17,500.00

Bio-engineering an Oncolytic Vaccinia Virus to Improve the Anti-Tumour Immune Response in Lung Cancer

FY 2016-17

Summary
Lung cancer is the leading cause of death from cancer in both men and women, yet the long-term survival rates still remain poor. The improvement of cancer treatment is dependent upon the development of new therapeutics that can act alone or together with existing therapeutics. Cancer-killing viruses known as oncolytic viruses (OVs) have the potential to be this therapeutic. Not only do oncolytic viruses target cancer cells, but they also activate the patient's own immune system against cancer. Vaccinia virus in particular has proven successful as an OV. There are, however, many immune-modulating genes within the Vaccinia viral genome that may play a role in the activation of the immune system. We propose the development of a system that creates random mutations in the Vaccinia genome. We will subsequently screen for mutants that can more effectively activate the patient's immune system. This will allow for the production of a large and comprehensive library of Vaccinia OVs that could be used in the clinical setting. By studying the cancer-specific immune-stimulating properties of these new Vaccinia virus clones, we will more fully understand the way in which OVs target and kill cancer cells. This will also allow for the production of a more effective oncolytic-immunotherapeutic for the treatment of aggressive cancers, such as lung cancer.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
367221
Name
Market Marisa
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Bio-engineering an Oncolytic Vaccinia Virus to Improve the Anti-Tumour Immune Response in Lung Cancer
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Immunology; Lung Cancer; Oncology; Virology
Abstract
Lung cancer is the leading cause of death from cancer in both men and women, yet the long-term survival rates still remain poor. The improvement of cancer treatment is dependent upon the development of new therapeutics that can act alone or together with existing therapeutics. Cancer-killing viruses known as oncolytic viruses (OVs) have the potential to be this therapeutic. Not only do oncolytic viruses target cancer cells, but they also activate the patient's own immune system against cancer. Vaccinia virus in particular has proven successful as an OV. There are, however, many immune-modulating genes within the Vaccinia viral genome that may play a role in the activation of the immune system. We propose the development of a system that creates random mutations in the Vaccinia genome. We will subsequently screen for mutants that can more effectively activate the patient's immune system. This will allow for the production of a large and comprehensive library of Vaccinia OVs that could be used in the clinical setting. By studying the cancer-specific immune-stimulating properties of these new Vaccinia virus clones, we will more fully understand the way in which OVs target and kill cancer cells. This will also allow for the production of a more effective oncolytic-immunotherapeutic for the treatment of aggressive cancers, such as lung cancer.
Competitiondate
201612
Approvedterm2
1 yr 0 mth
Pinamesdelim
Market, Marisa
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~